Results 41 to 50 of about 16,634 (253)
Effective treatment of a steroid-induced femoral neck fracture nonunion with a once-weekly administration of teriparatide in a rheumatoid patient: a case report [PDF]
, 2013 INTRODUCTION: Nonunion of femoral neck fractures frequently occurs in elderly patients. In patients with rheumatoid arthritis, reoperation rates after internal fixation of a displaced femoral neck fracture increase by up to 60 %.
Yuichi Mitani
core +1 more source
Severe hypercalcemia due to teriparatide
Indian Journal of Pharmacology, 2012 Osteoporosis that is by far the most common metabolic bone disease, has been defined as a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Anabolic therapy with teriparatide, recombinant human parathyroid hormone (PTH 1-34), stimulates bone formation and resorption and improves ...
KAYATAS, K +6 more
openaire +5 more sources
Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis? [PDF]
Asian Spine Journal, 2017 Study DesignRetrospective case series.PurposeThe purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF ...
Seiji Ohtori +16 more
doaj +1 more source
, 2014 Osteoporosis is a chronic, progressive disease characterized by low bone mass, bone deterioration, and decreased bone strength resulting in bone fragility and increased fracture risk.
Arthur Chernoff Md +2 more
core +1 more source
Recent Developments in Osteogenesis Imperfecta [PDF]
, 2015 Osteogenesis imperfecta (OI) is an uncommon genetic bone disease associated with brittle bones and fractures in children and adults. Although OI is most commonly associated with mutations of the genes for type I collagen, many other genes (some ...
Albert, Carolyne +3 more
core +2 more sources
Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. [PDF]
, 2017 Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density.
Aubry-Rozier, B. +11 more
core +4 more sources
Teriparatide - Indications beyond osteoporosis
Indian Journal of Endocrinology and Metabolism, 2012 Osteoporosis is a condition of impaired bone strength that results in an increased risk of fracture. The current and most popular pharmacological options for the treatment of osteoporosis include antiresorptive therapy, in particular, oral bisphosphonates (alendronate, risedronate, ibandronate).
Marilyn Lee Cheng, Vishal Gupta
openaire +4 more sources
Adult Hypophosphatasia Treated with Teriparatide [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2007 Hypophosphatasia (HPP) features low serum alkaline phosphatase (ALP) activity (hypophosphatasemia) due to loss-of-function mutation within TNSALP, the gene that encodes "tissue-nonspecific" ALP (TNSALP). Consequently, inorganic pyrophosphate accumulates extracellularly and impairs skeletal mineralization.
Michael P. Whyte +4 more
openaire +3 more sources
Journal of Orthopaedic Surgery and Research, 2023 Background Continuous use of glucocorticoids (GCs) has become the primary cause of secondary osteoporosis. Bisphosphonate drugs were given priority over denosumab and teriparatide in the 2017 American College of Rheumatology (ACR) guidelines but have a ...
Chuanjian Yuan +3 more
doaj +1 more source
Effectiveness of Teriparatide on Fracture Healing: A Systematic Review and Meta-Analysis.
PLoS ONE, 2016 PurposeNowadays, the efficacy of teriparatide in treating osteoporosis was widely accepted, but the discussion about using teriparatide to enhance fracture healing hasn't come to an agreement.
Zhongju Shi +7 more
doaj +1 more source